Opendata, web and dolomites

MPT system

Innovative, cost-effective, ultra-compact MRI-guided therapy system for diagnosis and immediate treatment of Parkinson's Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MPT system project word cloud

Explore the words cloud of the MPT system project. It provides you a very rough idea of what is the project "MPT system" about.

sized    primarily    conjunction    preliminary    journals    conferences    patents    scientific    magnetic    particle    disease    additional    dbs    movement    performed    trouble    insure    ultra    procedure    treatment    infections    fast    deep    save    treatments    peer    medication    weighs    disorders    setup    labor    initial    tested    ip    consisting    hospitals    population    regions    drug    pd    shielding    excellent    purchase    people    electrical    space    surgical    forecast    italy    incidence    stiffness    competitors    contacts    brain    mpt    supply    image    patients    requiring    spain    placement    feasibility    investment    clinical    anymore    sell    medical    valuable    invasive    nanoparticles    serious    currently    hemorrhages    double    updated    2050    walking    continues    tremors    saving    perfectly    guided    machine    neuroparticle    head    parkinson    stimulation    chain    estimates    therapy    complications    published    2m    breakthroughs    kg    compact    ageing    presented    afflicted    private    technological    responsible    installation    size    germany    trials    markets    relative   

Project "MPT system" data sheet

The following table provides information about the project.

Coordinator
NEUROPARTICLE EU LIMITED 

Organization address
address: UNIT 6 QUEENS YARD, WHITE POST LANE
city: LONDON
postcode: E9 5EN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://neuroparticle.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NEUROPARTICLE EU LIMITED UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Currently, there are 1.2M people afflicted by Parkinson’s disease (PD) only in EU and the incidence is forecast to double by 2050 primarily as a result of the ageing population. They require high invasive treatments when drug therapy and early medication are not effective anymore. Then, Deep Brain Stimulation (DBS) is the most commonly performed surgical treatment for Parkinson's patients, consisting in electrical stimulation of the deep regions of the brain responsible for movement disorders such tremors, stiffness and trouble walking. However, this treatment is highly-invasive and may lead to serious complications like hemorrhages and infections. Neuroparticle developed the Magnetic Particle Therapy (MPT), an ultra-compact, low-cost and non-invasive system for DBS in PD treatment. This stimulation is performed by image-guided placement of magnetic nanoparticles into the brain. The Neuroparticle’s system has been tested in various pre-clinical trials with excellent results published on peer- reviewed medical journals and presented at scientific conferences. This technological breakthroughs also enables meaningful reduction in size as it weighs only 90 kg and is perfectly head-sized (no shielding needed), saving hospitals valuable space and requiring less initial investment on setup labor. Finally, preliminary cost estimates show that the Neuroparticle’s system will allow hospitals to save up to 2/3 on cost of purchase and installation relative to competitors. During the Phase 1 feasibility assessment, in conjunction with partners, Neuroparticle will identify specific private hospitals to sell to. Target markets of Germany, Italy and Spain will be sized and contacts established. A supply chain procedure will be established in order to insure fast delivery for machine setup. As R&D continues, additional IP will be updated via patents.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MPT SYSTEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MPT SYSTEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More